Major Investor 5AM Ventures Exits Rallybio with $4.07M Share Sale Following Failed Merger
Summary
5AM Ventures, a major institutional investor, has fully sold its stake in Rallybio Corp for $4.07 million, coinciding with the termination of the company's reverse merger.
Key Events
-
Institutional Investor Exits
5AM Ventures, a significant institutional investor, sold all of its 291,788 shares of Rallybio common stock, indicating a complete divestment of their position.
-
Significant Share Sale Value
The shares were sold in open market transactions on May 4, 2026, at a weighted average price of $13.95 per share, totaling approximately $4.07 million.
-
Coincides with Failed Merger
This complete divestment occurred on the same day Rallybio announced the termination of its reverse merger agreement with Candid Therapeutics, suggesting a reaction to the failed strategic event.
Analysis
This Schedule 13D/A reports that 5AM Ventures, a significant institutional investor, has fully divested its stake in Rallybio Corp by selling 291,788 shares for approximately $4.07 million. This complete exit, representing over 5% of the company's market capitalization, occurred on May 4, 2026, the same day Rallybio announced the termination of its reverse merger agreement with Candid Therapeutics. The timing suggests a loss of confidence from a major investor following the collapse of the strategic transaction, which could put further pressure on the stock.
At the time of this filing, RLYB was trading at $14.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77M. The 52-week trading range was $2.16 to $15.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.